140 related articles for article (PubMed ID: 17886239)
1. The chakragati mouse: a mouse model for rapid in vivo screening of antipsychotic drug candidates.
Dawe GS; Ratty AK
Biotechnol J; 2007 Nov; 2(11):1344-52. PubMed ID: 17886239
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse.
Dawe GS; Nagarajah R; Albert R; Casey DE; Gross KW; Ratty AK
Neuroscience; 2010 Nov; 171(1):162-72. PubMed ID: 20816926
[TBL] [Abstract][Full Text] [Related]
3. The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition.
Verma V; Tan CH; Ong WY; Grigoryan GA; Jones CA; Stolzberg D; Salvi R; Gross KW; Ratty AK; Dawe GS
Neurosci Res; 2008 Mar; 60(3):281-8. PubMed ID: 18164085
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evidence for reduced social interactions in Chakragati mutants modeling certain symptoms of schizophrenia.
Torres G; Meeder BA; Hallas BH; Gross KW; Horowitz JM
Brain Res; 2005 Jun; 1046(1-2):180-6. PubMed ID: 15882844
[TBL] [Abstract][Full Text] [Related]
5. A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia.
Torres G; Hallas BH; Vernace VA; Jones C; Gross KW; Horowitz JM
Brain Res Bull; 2004 Jan; 62(4):315-26. PubMed ID: 14709346
[TBL] [Abstract][Full Text] [Related]
6. Ventricular size mapping in a transgenic model of schizophrenia.
Torres G; Meeder BA; Hallas BH; Spernyak JA; Mazurchuk R; Jones C; Gross KW; Horowitz JM
Brain Res Dev Brain Res; 2005 Jan; 154(1):35-44. PubMed ID: 15617753
[TBL] [Abstract][Full Text] [Related]
7. Specificity of behavioral and neurochemical dysfunction in the chakragati mouse: a novel genetic model of a movement disorder.
Fitzgerald LW; Ratty AK; Teitler M; Gross KW; Glick SD
Brain Res; 1993 Apr; 608(2):247-58. PubMed ID: 8495359
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of antipsychotic and relative drugs using disruption of prepulse inhibition as an animal model for schizophrenia].
Suemaru K; Kohnomi S; Umeda K; Araki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Jun; 28(3):121-6. PubMed ID: 18646597
[TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
Millan MJ; Brocco M
Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic drug actions on gene modulation and signaling mechanisms.
Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
[TBL] [Abstract][Full Text] [Related]
11. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration.
McOmish CE; Burrows E; Howard M; Scarr E; Kim D; Shin HS; Dean B; van den Buuse M; Hannan AJ
Mol Psychiatry; 2008 Jul; 13(7):661-72. PubMed ID: 17667964
[TBL] [Abstract][Full Text] [Related]
12. Use of biomarkers in the discovery of novel anti-schizophrenia drugs.
Mikkelsen JD; Thomsen MS; Hansen HH; Lichota J
Drug Discov Today; 2010 Feb; 15(3-4):137-41. PubMed ID: 20036755
[TBL] [Abstract][Full Text] [Related]
13. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery.
Hajós M
Trends Pharmacol Sci; 2006 Jul; 27(7):391-8. PubMed ID: 16766049
[TBL] [Abstract][Full Text] [Related]
14. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
15. Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity.
Galici R; Boggs JD; Miller KL; Bonaventure P; Atack JR
Behav Pharmacol; 2008 Mar; 19(2):153-9. PubMed ID: 18332680
[TBL] [Abstract][Full Text] [Related]
16. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models.
Watanabe Y; Someya T; Nawa H
Psychiatry Clin Neurosci; 2010 Jun; 64(3):217-30. PubMed ID: 20602722
[TBL] [Abstract][Full Text] [Related]
17. Behavioral animal models of antipsychotic drug actions.
Peleg-Raibstein D; Feldon J; Meyer U
Handb Exp Pharmacol; 2012; (212):361-406. PubMed ID: 23129339
[TBL] [Abstract][Full Text] [Related]
18. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges.
Williams M
Biochem Pharmacol; 2009 Dec; 78(11):1360-5. PubMed ID: 19591808
[TBL] [Abstract][Full Text] [Related]
19. Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo.
Del'guidice T; Beaulieu JM
Mol Pharmacol; 2008 May; 73(5):1339-42. PubMed ID: 18314495
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
